Effect of Dexmedetomidine As Adjuvant to Ropivacaine for Brachial Plexus Block
NCT ID: NCT05767827
Last Updated: 2024-09-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
40 participants
INTERVENTIONAL
2023-02-01
2024-08-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dexamethasone Compared With Dexmedetomidine as an Adjuvant to Ropivacaine for Supraclavicular Brachial Plexus Block
NCT02787018
Comparison Of Dexmedetomidine And Dexamethasone As An Adjuvant To Bupivacaine In Brachial Plexus Block
NCT04791475
Supraclavicular Brachial Plexus Block Using Ropivacaine Alone and With Dexmedetomidine
NCT02393677
Dexamethasone as an Adjuvant to Ropivacaine for the Interscalene Brachial Plexus Block
NCT02818491
The Effect of Dexmedetomidine on Brachial Plexus Block for Shoulder Surgery
NCT02225054
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group R
0.35% ropivacaine 20ml, 1.5% lidocaine with adrenaline 10ml = 30 ml
ropivacaine, lidocaine with adrenaline
Group R includes 0.35% ropivacaine 20ml, 1.5 % lidocaine with adrenaline 10ml
Group RD
0.35% ropivacaine and 1mcg/ kg dexmedetomidine (20 ml), 1.5% lidocaine with adrenaline (10ml) = 30 ml
Dexmedetomidine, ropivacaine, lidocaine with adrenaline
Dexmedetomidine 1mcg/kg and 0.35% ropivacaine with normal saline (20ml), 1.5% lidocaine with adrenaline (10ml) in group RD
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ropivacaine, lidocaine with adrenaline
Group R includes 0.35% ropivacaine 20ml, 1.5 % lidocaine with adrenaline 10ml
Dexmedetomidine, ropivacaine, lidocaine with adrenaline
Dexmedetomidine 1mcg/kg and 0.35% ropivacaine with normal saline (20ml), 1.5% lidocaine with adrenaline (10ml) in group RD
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Elective upper limb surgery under brachial plexus block
Exclusion Criteria
* Pregnant or lactating mothers
* Hepatic, renal or cardiopulmonary abnormalities
* Long term analgesic therapy
20 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nepal Medical College and Teaching Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Rajiv Yadav
Lecturer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nepal medical college
Kathmandu, Bagmati, Nepal
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NepalMCTH
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.